Medical Digest & Congress Report

Professor Gregg W. Stone shared his insights on the ULTIMATE-DAPT study. Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding with no increased thrombotic risk. Video: https://medicaldigest.org/scientific-contents/interview:ultimate-dapt-most-patients-acs-can-safely-sto...

Professor Javed Butler shared his insights on the EMPACT-MI study. The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure or death from any cause among patients with an increased risk for HF following acute myocardial infarction, according to the results of the EMPACT-MI study. Video: https://medicaldigest.org/scientific-contents/interview:empact-mi-e...

Professor Steven E. Nissen shared his insights on the TACTiC study, presented during a Late-Breaking Clinical Trial session at ACC.24. The study proved that the method improves lipid control and adherence. Video: https://medicaldigest.org/scientific-contents/interview:outcomes-after-technology-assisted-nonprescription-rosuvastatin-administration-tactic-trial

ACC President B. Hadley Wilson shared his insights on Late-Breaking Clinical Trials I, presented during at ACC.24: -  RELIEVE-HF: Does Impact of Interatrial Shunting Differ By HF Type? -  EMPACT-MI: Empagliflozin Post MI Does Not Lower Risk of First HF Hospitalization, Death -  AEGIS-II: CSL112 Associated With Lower Rates of CV Death, MI Video: https://medicaldigest.org/scientific-contents/intervi...

Professor Robert Roswell shared his insights on the DanGer Shock trial. Implantation of the Impella CP micro-axial flow pump in the hours after a heart attack significantly increased the rate of survival at six months among people suffering cardiogenic shock, according to a study presented at the American College of Cardiology's Annual Scientific Session. Video: https://medicaldigest.org/scien...

Dr. Yakubu Bene-Alhasan shared his insights on the large study that adds to growing body of evidence that vaping may harm the heart. People who use e-cigarettes are significantly more likely to develop heart failure compared with those who have never used them, according to one of the largest prospective studies to date investigating possible links between vaping and heart failure. Video: https://...

We asked Professor Stefan N. Symeonides, one of the authors of the KEYNOTE-564 study, about the trial and the new data presented on overall survival at ASCO GU 2024. Adjuvant treatment with pembrolizumab has significantly improved overall survival in patients with clear cell renal cell carcinoma who are at high risk of recurrence after surgery, according to an updated analysis of the KEYNOTE-564 t...

We asked Professor David F. McDermott, investigator of the KEYNOTE-564 study, about the trial and the new data presented on overall survival at ASCO GU 2024. Video: https://medicaldigest.org/scientific-contents/standalonecontent:overall-survival-results-keynote-564-adjuvant-pembrolizumab-versus-placebo-renal-cell-carcinoma

Professor Carla Casulo summarizes the most important highlights in the field of Follicular Lymphoma treatment after the 65th American Society of Hematology Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:follicular-lymphoma-highlights-ash-2023-congress

Professor on frontline treatment with targeted agents in patients with Chronic Lymphocytic Leukemia. Video: https://medicaldigest.org/scientific-contents/interview:frontline-treatment-targeted-agents-patients-chronic-lymphocytic-leukemia-report-ash2023

Professor Swetha Kambhampati on Mantle Cell Lymphoma: Real-World Outcomes With Brexucabtagene Autoleucel. Video: https://medicaldigest.org/scientific-contents/interview:real-world-outcomes-brexucabtagene-autoleucel

Professor Michael Wang explains their findings that combining ibrutinib and venetoclax improves progression-free survival and remission rates in patients with mantle cell lymphoma. Video: https://medicaldigest.org/scientific-contents/interview:ibrutinib-venetoclax-combination-found-effective-against-mantle-cell-lymphoma

Professor Xavier Leleu explains the present and future of Multiple Myeloma management, how new regiments, new treatments will change how we treat patients. Video: https://medicaldigest.org/scientific-contents/interview:present-and-future-multiple-myeloma-management

Professor Mikkael Sekeres summarizes the most important highlights that presented at the 65th American Society of Hematology Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:highlights-ash-2023-congress

Professor Carmen Fava summarizes the therapeutic novelties of Chronic Myeloid Leukemia management at the 65th American Society of Hematology Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:chronic-myeloid-leukemia-novel-therapeutic-approaches

Professor Eunice S. Wang summarizes the most important highlights in the field of Acute Myeloid Leukemia treatment at the 65th American Society of Hematology Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:acute-myeloid-leukemia-highlights-ash-2023-congress-2

Professor Giuseppe Saglio summarizes the most important highlights in the field of Chronic Myeloid Leukemia treatment at the 65th American Society of Hematology Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:chronic-myeloid-leukemia-highlights-ash-2023-congress

Professor Andrzej Jakubowiak summarizes the most important highlights in the field of MultiplMyeloma treatment at the 65th American Society of Hematology Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:multiple-myeloma-highlights-ash-2023-congress

Dr. Alissa Visram on the presented the data during 65th American Society of Hematology Annual Meeting. Patients with multiple myeloma who were treated in the real world had 44% worse progression-free survival and 75% worse overall survival than patients treated on clinical trials, according to a pooled analysis of efficacy versus effectiveness for seven MM regimens. Video: https://medicaldigest.or...

Professor Marlise R. Luskin summarizes the state of the art acute lymphoblastic leukemia treatement at the 65th American Society of Hematology Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:state-art-all-treatement-2023

Professor Agnieszka Wierzbowska summarizes the most important highlights in the field of acute myeloid leukemia treatment at the 65th American Society of Hematology Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:acute-myeloid-leukemia-highlights-ash-2023-congress

Professor Enrique Ocio summarizes the diagnostic and therapeutic novelties of Multiple Myeloma management at the 65th American Society of Hematology Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:diagnostic-and-therapeutic-novelties-multiple-myeloma-management

Professor Umberto Vitolo summarizes the most important highlights in the field of Non-Hodgkin Lymphoma treatment at the 65th American Society of Hematology Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:non-hodgkin-lymphoma-highlights-ash-2023-congress

Professor Pieter Sonneveld explains that newly diagnosed patients with multiple myeloma who received daratumumab along with the standard care regimen of bortezomib, lenalidomide, and dexamethasone showed significantly higher rates of survival without disease progression compared with those who received VRd alone. Results from the phase III Perseus trial were reported at the 2023 ASH Annual Meeting...

Professor Ibrahim Aldoss explains that patients with relapsed or refractory acute leukemia with rearrangement in the lysine methyltransferase 2a gene, a genetic marker known as KMT2Ar, who were treated with revumenib saw an overall response rate of 63%, according to results from a phase II trial being reported during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. Vide...